APPROVED: Antares seeks niche in US arthritis market with Otrexup
This article was originally published in Scrip
Executive Summary
With the US FDA's approval of Otrexup, patients with arthritis for whom oral methotrexate is no longer adequate have a new once-a-week option, while Antares Pharma is hoping to grab a piece of the market.